Kupando

About:

Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.

Top Investors: HTGF | High-Tech Gruenderfonds, Brandenburg Kapital, Remiges Ventures, LifeCare Partners, Ventura BioMed Investors

Description:

KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.

Total Funding Amount:

13M EUR

Headquarters Location:

Schönefeld, Brandenburg, Germany

Founded Date:

2018-01-01

Founders:

Johanna Holldack

Number of Employees:

1-10

Last Funding Date:

2022-09-26

IPO Status:

Private

Industries: